Dr. Michelle Marie Squadrito, MD

Dr. Squadrito practices at ENT and Allergy of Delaware in Newark, Delaware.

Dr. Squadrito's NPI, 1518347095, was assigned on June 1, 2015. Dr. Squadrito graduated from Temple University School of Medicine in 2015. Dr. Squadrito holds Delaware license C1-0013781.

Dr. Squadrito's primary practice is ENT and Allergy of Delaware, at 700 Prides Xing, Newark, DE 19713 in New Castle County. The practice phone is (302) 998-0300.

Dr. Squadrito's primary practice is ENT and Allergy of Delaware in Newark, Delaware. Dr. Squadrito is also affiliated with Christiana Hospital. The medical group on file is ENT & Allergy of Delaware. Dmand AI also links Dr. Squadrito to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Squadrito practices, 2 sites in all. Vendor and product names are available with a free account.

Allergy and immunology is Dr. Squadrito's primary specialty in the NPI Registry, under taxonomy code 207K00000X. Dmand AI has Dr. Squadrito's licenses on file in 2 states: Delaware and Pennsylvania.

CMS data shows 1,981 Medicare services from Dr. Squadrito across 9 procedure codes in 2024, for 363 Medicare patients. Medicare paid $19,360 for them. Every service was in an office.

CMS counts 363 Medicare patients who saw Dr. Squadrito in 2024. The largest group is 65 to 74, with 220 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 7% are also on Medicaid. Their average risk score is 0.86, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Squadrito's median patient age at 38, with 59% women.

In 2024, Dr. Squadrito wrote 249 Medicare Part D claims for 61 patients. 71% of them were for generic drugs. CMS names the drug for 185 of them, across 6 drugs with 11 or more claims each, at $41,651 in total drug cost. In 2023, CMS named 162 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Squadrito for performance year 2024, reported as part of a group. Dr. Squadrito accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 256 general payments to Dr. Squadrito from 30 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 90% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $1,299.

Dr. Squadrito graduated from Temple University School of Medicine in 2015.